Drugs / VX-634
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05579431 | Oct 2022 → May 2023 | alpha 1-antitrypsin deficiency | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-10-11 | Vertex Pharmaceuticals Incorporated | Regulatory Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency vrtx.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-10-11 | Vertex Pharmaceuticals Incorporated | Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency vrtx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-634 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05579431 ↗ |
| Route | Oral | “Suspension for oral administration.” NCT05579431 ↗ |